AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 51-75/114
ALLOGENEIC TRANSPLANTATION FOR ADVANCED LEUKEMIA - IMPROVED SHORT-TERM OUTCOME WITH BLOOD STEM-CELL GRAFTS AND TACROLIMUS
Authors: PRZEPIORKA D IPPOLITI C KHOURI I ANDERLINI P MEHRA R GIRALT S GAJEWSKI J FRITSCHE H DEISSEROTH AB CLEARY K CHAMPLIN R VANBESIEN K ANDERSSON B KORBLING M
Citation: D. Przepiorka et al., ALLOGENEIC TRANSPLANTATION FOR ADVANCED LEUKEMIA - IMPROVED SHORT-TERM OUTCOME WITH BLOOD STEM-CELL GRAFTS AND TACROLIMUS, Transplantation, 62(12), 1996, pp. 1806-1810
TACROLIMUS AND MINIDOSE METHOTREXATE FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MATCHED UNRELATED DONOR MARROW TRANSPLANTATION
Authors: PRZEPIORKA D IPPOLITI C KHOURI I WOO M MEHRA R LEBHERZ D GIRALT S GAJEWSKI J FISCHER H FRITSCHE H DEISSEROTH AB CLEAN K CHAMPLIN R VANBESIEN K ANDERSSON B MAHER R FITZSIMMONS W
Citation: D. Przepiorka et al., TACROLIMUS AND MINIDOSE METHOTREXATE FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MATCHED UNRELATED DONOR MARROW TRANSPLANTATION, Blood, 88(11), 1996, pp. 4383-4389
RESULTS WITH DECITABINE, A HYPOMETHYLATING AGENT, IN THE TREATMENT OFCHRONIC MYELOGENOUS LEUKEMIA (CML) IN ACCELERATED OR ELASTIC PHASES
Authors: KANTARJIAN H OBRIEN S BERAN M GIRALT S ESTEY E KOLLER C KORNBLAU S ANDREEFF M DEVOS D KEATING M TALPAZ M
Citation: H. Kantarjian et al., RESULTS WITH DECITABINE, A HYPOMETHYLATING AGENT, IN THE TREATMENT OFCHRONIC MYELOGENOUS LEUKEMIA (CML) IN ACCELERATED OR ELASTIC PHASES, Blood, 88(10), 1996, pp. 3522-3522
MYELOABLATIVE TREATMENT FOR MULTIPLE-MYELOMA
Authors: ALEXANIAN R WEBER D DELASALLE K DIMOPOULOS M GIRALT S CHAMPLIN R
Citation: R. Alexanian et al., MYELOABLATIVE TREATMENT FOR MULTIPLE-MYELOMA, Blood, 88(10), 1996, pp. 3602-3602
PREDICTING OUTCOME OF CHRONIC MYELOGENOUS LEUKEMIA (CML) POST ALLOGENEIC MARROW TRANSPLANTATION BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION (RT-PCR)
Authors: KHOURI I CHAMPLIN R PRZEPIORKA D GIRALT S THALL P KANTARJIAN H CHENG SC MIRZA NQ DEISSEROTH AB LEE MS
Citation: I. Khouri et al., PREDICTING OUTCOME OF CHRONIC MYELOGENOUS LEUKEMIA (CML) POST ALLOGENEIC MARROW TRANSPLANTATION BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION (RT-PCR), Blood, 88(10), 1996, pp. 3802-3802
HYPER-CVAD AND HIGH-DOSE METHOTREXATE ARA-C (HD MTX-ARA-C) FOLLOWED BY STEM-CELL TRANSPLANTATION FOR AGGRESSIVE MANTLE CELL LYMPHOMA (MCL)/
Authors: KHOURI I ROMAGUERA J KANTARJIAN H PUGH W PRZEPIORKA D RODRIGUEZ A SAMUELS BI VANBESIEN K GIRALT S MCLAUGHLIN P CLAXTON D MIRZA NO GAJEWSKI J MEHRA R HAGEMEISTER F CABANILLAS F CHAMPLIN R
Citation: I. Khouri et al., HYPER-CVAD AND HIGH-DOSE METHOTREXATE ARA-C (HD MTX-ARA-C) FOLLOWED BY STEM-CELL TRANSPLANTATION FOR AGGRESSIVE MANTLE CELL LYMPHOMA (MCL)/, Blood, 88(10), 1996, pp. 475-475
AUTOLOGOUS TRANSPLANTATION (ABMT) IS A CURATIVE TREATMENT FOR PATIENTS (PTS) WITH RECURRENT AND REFRACTORY PRIMARY MEDIASTINAL LYMPHOMA (PML)
Authors: POPAT U VANBESIEN K AMIN K GIRALT S MEHRA R KHOURI I WILLIAMS P ANDERSSON B PRZEPIORKA D GAJEWSKI J CHAMPLIN R
Citation: U. Popat et al., AUTOLOGOUS TRANSPLANTATION (ABMT) IS A CURATIVE TREATMENT FOR PATIENTS (PTS) WITH RECURRENT AND REFRACTORY PRIMARY MEDIASTINAL LYMPHOMA (PML), Blood, 88(10), 1996, pp. 485-485
TANDEM HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS BONE-MARROW RESCUE(BMR) IN BREAST-CANCER
Authors: DELIMA M MEHRA R VANBESIEN K GIRALT S BELLARE N GAJEWSKI J KHOURI I ANDERSSON B PRZEPIORKA D RONDON G GEISLER D HORTOBAGYI G CHAMPLIN R
Citation: M. Delima et al., TANDEM HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS BONE-MARROW RESCUE(BMR) IN BREAST-CANCER, Blood, 88(10), 1996, pp. 503-503
ENGRAFTMENT AND INDUCTION OF GVL WITH FLUDARABINE (FAMP)-BASED NON-ABLATIVE PREPARATIVE REGIMEN IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) AND LYMPHOMA
Authors: KHOURI I KEATING MJ PRZEPIORKA D OBRIEN S GIRALT S KORBLING M CHAMPLIN R
Citation: I. Khouri et al., ENGRAFTMENT AND INDUCTION OF GVL WITH FLUDARABINE (FAMP)-BASED NON-ABLATIVE PREPARATIVE REGIMEN IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) AND LYMPHOMA, Blood, 88(10), 1996, pp. 1194-1194
MICRODOSE METHOTREXATE VS METHYLPREDNISOLONE IN COMBINATION WITH TACROLIMUS FOR PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE (GVHD) AFTER ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION
Authors: PRZEPIORKA D IPPOLITI C KHOURI I ANDERLINI P LEBHERZ D VANBESIEN K UENO N MEHRA R GIRALT S GAJEWSKI J FRITSCHE H CLEARY K CLAXTON D CHAMPLIN R ANDERSSON B KORBLING M
Citation: D. Przepiorka et al., MICRODOSE METHOTREXATE VS METHYLPREDNISOLONE IN COMBINATION WITH TACROLIMUS FOR PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE (GVHD) AFTER ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION, Blood, 88(10), 1996, pp. 1659-1659
ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION FOR INDUCTION OF GRAFT VERSUS TUMOR EFFECT IN PATIENTS WITH METASTATIC BREAST-CANCER
Authors: UENO NT RONDON G GEISLER D GIRALT S MEHRA R PRZEPIORKA D ANDERSSON B GAJEWSKI J KHOURI I KORBLING M SEONG D RAHMAN Z VANBESIEN K ANDERLINI P HORTOBAGYI G CHAMPLIN RE
Citation: Nt. Ueno et al., ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION FOR INDUCTION OF GRAFT VERSUS TUMOR EFFECT IN PATIENTS WITH METASTATIC BREAST-CANCER, Blood, 88(10), 1996, pp. 2440-2440
INDUCTION OF GRAFT-VERSUS-LEUKEMIA WITHOUT MYELOABLATIVE THERAPY USING ALLOGENEIC PBSC AFTER PURINE ANALOG CONTAINING REGIMENS
Authors: GIRALT S ESTEY E VANBESIEN K RONDON G OBRIEN S KHOURI I GAJEWSKI J MEHRA R CLAXTON D BERAN M ANDERSSON B PRZEPIORKA D KOLLER C KORBLAU S ALBITAR M KORBLING M KANTARJIAN H CHAMPLIN R
Citation: S. Giralt et al., INDUCTION OF GRAFT-VERSUS-LEUKEMIA WITHOUT MYELOABLATIVE THERAPY USING ALLOGENEIC PBSC AFTER PURINE ANALOG CONTAINING REGIMENS, Blood, 88(10), 1996, pp. 2444-2444
EXPERIENCE WITH 100 HLA-IDENTICAL, ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATIONS - CD34+ CELL DOSE AND ENGRAFTMENT
Authors: KORBLING M MIRZA N THALL P HUH Y FISCHER H FAHMY H PRZEPIORKA D ANDERLINI P MEHRA R CLAXTON D ANDERSSON B VANBESIEN K KHOURI I GAJEWSKI J GIRALT S CHAMPLIN R
Citation: M. Korbling et al., EXPERIENCE WITH 100 HLA-IDENTICAL, ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATIONS - CD34+ CELL DOSE AND ENGRAFTMENT, Blood, 88(10), 1996, pp. 2451-2451
HIGH-DOSE BEAM AS CONDITIONING FOR ALLOGENEIC TRANSPLANTATION IN LYMPHOID MALIGNANCIES
Authors: VANBESIEN K GIRALT S MEHRA R KHOURI I RODRIGUEZ A ANDERSSON B KORBLING M PRZEPIORKA D CABANILLAS F CHAMPLIN R
Citation: K. Vanbesien et al., HIGH-DOSE BEAM AS CONDITIONING FOR ALLOGENEIC TRANSPLANTATION IN LYMPHOID MALIGNANCIES, Blood, 88(10), 1996, pp. 2459-2459
EARLY DETECTION OF RELAPSE BY HYPERMETAPHASE FISH AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA
Authors: SEONG D GIRALT S KANTARJIAN H XU JP SWANTKOWSKI J HAYES K GLASSMAN AB ALBITAR M KHOURI I KORBLING M SICILIANO MJ CHAMPLIN RE
Citation: D. Seong et al., EARLY DETECTION OF RELAPSE BY HYPERMETAPHASE FISH AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA, Blood, 88(10), 1996, pp. 2645-2645
EFFECT OF PRIOR INTERFERON THERAPY ON OUTCOME OF HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) IN FIRST CHRONIC PHASE
Authors: HOROWITZ MM GIRALT S SZYDLO R GOLDMAN J VEUMSTONE J
Citation: Mm. Horowitz et al., EFFECT OF PRIOR INTERFERON THERAPY ON OUTCOME OF HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) IN FIRST CHRONIC PHASE, Blood, 88(10), 1996, pp. 2716-2716
T-CELLS, GRAFT-VERSUS-HOST DISEASE AND GRAFT-VERSUS-LEUKEMIA - INNOVATIVE APPROACHES FOR BLOOD AND MARROW TRANSPLANTATION
Authors: CHAMPLIN R GIRALT S GAJEWSKI J
Citation: R. Champlin et al., T-CELLS, GRAFT-VERSUS-HOST DISEASE AND GRAFT-VERSUS-LEUKEMIA - INNOVATIVE APPROACHES FOR BLOOD AND MARROW TRANSPLANTATION, Acta haematologica, 95(3-4), 1996, pp. 157-163
INTERFERON-ALPHA AND INTERLEUKIN-2 AS TREATMENT FOR LEUKEMIA RELAPSE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: GIRALT S OBRIEN S TALPAZ M VANBESIEN K CHAN KW RONDON G ANDERSSON B MEHRA R KHOURI I ESTEY E CHAMPLIN R
Citation: S. Giralt et al., INTERFERON-ALPHA AND INTERLEUKIN-2 AS TREATMENT FOR LEUKEMIA RELAPSE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Cytokines and molecular therapy, 1(2), 1995, pp. 115-122
A PHASE I-II STUDY OF HIGH-DOSE THIOTEPA, BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION FOR MALIGNANT-LYMPHOMA
Authors: PRZEPIORKA D NATH R IPPOLITI C MEHRA R HAGEMEISTER F DIENER K DIMOPOULOS M GIRALT S KHOURI I SAMUELS B VANBESIEN K ANDERSSON B DEISSEROTH AB LUNA M CABANILLAS F CHAMPLIN R
Citation: D. Przepiorka et al., A PHASE I-II STUDY OF HIGH-DOSE THIOTEPA, BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION FOR MALIGNANT-LYMPHOMA, Leukemia & lymphoma, 17(5-6), 1995, pp. 427-433
CD8 DEPLETED DONOR LYMPHOCYTES FOR CML RELAPSING POST BMT
Authors: CHAMPLIN R GIRALT S GAJEWSKI J HESTER J KORBLING M DEISSEROTH A
Citation: R. Champlin et al., CD8 DEPLETED DONOR LYMPHOCYTES FOR CML RELAPSING POST BMT, Experimental hematology, 23(8), 1995, pp. 939-939
HIGH-DOSE CHEMOTHERAPY WITH BEAC REGIMEN AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR INTERMEDIATE GRADE AND IMMUNOBLASTIC LYMPHOMA - DURABLE COMPLETE REMISSIONS, BUT A HIGH-RATE OF REGIMEN-RELATED TOXICITY
Authors: VANBESIEN K TABOCOFF J RODRIGUEZ M ANDERSSON B MEHRA R PRZEPIORKA D DIMOPOULOS M GIRALT S SUKI S KHOURI I SPITZER G JAGANNATH S DICKE K LEMAISTRE CF DEISSEROTH A CABANILLAS F CHAMPLIN RE
Citation: K. Vanbesien et al., HIGH-DOSE CHEMOTHERAPY WITH BEAC REGIMEN AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR INTERMEDIATE GRADE AND IMMUNOBLASTIC LYMPHOMA - DURABLE COMPLETE REMISSIONS, BUT A HIGH-RATE OF REGIMEN-RELATED TOXICITY, Bone marrow transplantation, 15(4), 1995, pp. 549-555
TREATMENT OF LEUKEMIA RELAPSE AFTER BONE-MARROW TRANSPLANTATION WITH INTERFERON-ALPHA AND INTERLEUKIN-2
Authors: SHAFFER L GIRALT S CHAMPLIN R CHAN KW
Citation: L. Shaffer et al., TREATMENT OF LEUKEMIA RELAPSE AFTER BONE-MARROW TRANSPLANTATION WITH INTERFERON-ALPHA AND INTERLEUKIN-2, Bone marrow transplantation, 15(2), 1995, pp. 317-319
TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
Authors: GIRALT S KANTARJIAN H TALPAZ M
Citation: S. Giralt et al., TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA, Seminars in oncology, 22(4), 1995, pp. 396-404
THE NATURAL-HISTORY OF CHRONIC MYELOGENOUS LEUKEMIA IN THE INTERFERONERA
Authors: GIRALT S KANTARJIAN H TALPAZ M
Citation: S. Giralt et al., THE NATURAL-HISTORY OF CHRONIC MYELOGENOUS LEUKEMIA IN THE INTERFERONERA, Seminars in hematology, 32(2), 1995, pp. 152-158
CD8-DEPLETED DONOR LYMPHOCYTE INFUSION AS TREATMENT FOR RELAPSED CHRONIC MYELOGENOUS LEUKEMIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: GIRALT S HESTER J HUH Y HIRSCHGINSBERG C RONDON G SEONG D LEE M GAJEWSKI J VANBESIEN K KHOURI I MEHRA R PRZEPIORKA D KORBLING M TALPAZ M KANTARJIAN H FISCHER H DEISSEROTH A CHAMPLIN R
Citation: S. Giralt et al., CD8-DEPLETED DONOR LYMPHOCYTE INFUSION AS TREATMENT FOR RELAPSED CHRONIC MYELOGENOUS LEUKEMIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Blood, 86(11), 1995, pp. 4337-4343
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>